U.S. patents available from 1976 to present.
U.S. patent applications available from 2005 to present.

Ultrapure hyaluronic acid and the use thereof

Patent 4141973 Issued on February 27, 1979. Estimated Expiration Date: Icon_subject October 25, 1997. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Inventor

Assignee

Application

No. 05/844833 filed on 10/25/1977

US Classes:

514/54, Polysaccharide514/769, DESIGNATED INORGANIC NONACTIVE INGREDIENT OR ELEMENTAL MATERIAL OTHER THAN WATER536/55.1Polysaccharides

Examiners

Primary: Meyers, Albert T.
Assistant: Robinson, D. W.

Attorney, Agent or Firm

International Classes

C08B 37/00 (20060101)
C08B 37/00 (20060101)
C08B 37/08 (20060101)
C08B 37/08 (20060101)

Abstract

An ultra-pure, high molecular weight hyaluronic acid fraction which is characterized by the absence of significant cellular infiltration of the vitreous and anterior chamber, absence of significant flare in the aqueous humor, absence of significant haze or flare in the vitreous and absence of pathological changes to the cornea, lens, iris, retina, and choroid of the owl monkey eye when one milliliter of a 1% solution of the sodium salt thereof dissolved in physiological buffer is implanted in the vitreous replacing about one-half the existing liquid vitreous. This material is obtained from animal tissue containing hyaluronic acid by a process which comprises removing the blood from animal tissue containing hyaluronic acid, extracting hyaluronic acid therefrom, deproteinizing the hyaluronic acid extract, and removing any unidentified inflammation causing agents persent therein by treating the deproteinized hyaluronic acid extract at a pH of 6.0 - 7.0 with a volume of chloroform at least about equal to that of the deproteinized extract, to form a two-phase mixture which is then stirred, sufficiently to ensure intimate contact between said two phases, at about 15° - 40° C., followed by separating out and discarding the chloroform phase.

Other References

  • chem. Abst. 55, 4892(c) (1960)
  • Chem. Abst. 52, 16442(a) (1958)
  • Chem. Abst. 70, 326(f) (1969)
  • Chem. Abst. 67, 25397(f) (1967)
  • Chem. Abst. 54, 13237(a) (1960)
  • Chem. Abst. 48, 10826(h) (1954)
  • Chem. Abst., 8th Collective Index, pp. 15074(s)-15076(s), (1972)
  • Arch. Ophth. 88(11) pp. 544-548 (1972), Constable et al
  • Invest. Ophth. 11(3) pp. 164-168 (1972), Swann et al
  • Balaz et al., Mod. Probl. Ophthal. 10, pp. 3-21 (1972)
  • Regnault et al., Mod. Probl. Ophthal. 12, pp. 378-383 (1974)
  • Balaz et al. (New & Controversial Aspects of Retinol Detachment) pp. 371-376 (1968)
  • Castren, ACTA Opthth. 42
  • Morean et al., Ann. Oculist., pp. 493-501, (1968)
  • Girod et al., Ann. Oculist., pp. 25-40, (1970)
PatentsPlus Images
Enhanced PDF formats
loading...
PatentsPlus: add to cart
PatentsPlus: add to cartSearch-enhanced full patent PDF image
$9.95more info
 
Sign InRegister
Username  
Password   
forgot password?